Log In
Print this Print this

halofuginone (HT-100)

  Manage Alerts
Collapse Summary General Information
Company Akashi Therapeutics Inc.
DescriptionOral delayed-release formulation of halofuginone, a collagen type I (COL1) inhibitor
Molecular Target Collagen type I (COL1)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationMuscular dystrophy
Indication DetailsTreat Duchenne muscular dystrophy (DMD)
Regulatory Designation

U.S. - Fast Track (Treat Duchenne muscular dystrophy (DMD));
U.S. - Orphan Drug (Treat Duchenne muscular dystrophy (DMD));
EU - Orphan Drug (Treat Duchenne muscular dystrophy (DMD))


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today